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ABSTRACT
Objective: To analyze the safety of combined leflunomide (LEF), methotrexate
(MTX), and glucocorticoid (GC) therapy, we investigated the adverse effects of such
combination therapy in patients with early active rheumatoid arthritis (RA).
Methods: Two hundred sixty-six patients with RA who were receiving LEF and
MTX therapy were randomly assigned to 3 groups, as follows: group 1 received no
GC, group 2 received 7.5 mg prednisone, and group 3 received 15 mg prednisone.
Adverse effects were analyzed using the 2 test at week 4 or the Fisher exact test at
eek 12.
Results: Patients in group 1 had a higher incidence of skin rash, oral ulcers,
leukopenia, and liver damage than did those in groups 2 and 3 (all, P  0.05).
However, the rates of osteoporosis, diabetes, hyperlipidemia, and hypertension in
group 3 were statistically higher than in groups 1 and 2 (P  0.05).
Conclusion: In the treatment of RA, the incidence of skin rash, liver dysfunction,
and oral ulcers may be decreased with combination therapy using LEF, MTX, and 7.5 mg
prednisone, and blood pressure, blood glucose concentration, and bone density are not
increased. Most important, 7.5 mg prednisone was synergistic with LEF and MTX, and
such combination therapy could be a useful option as initial treatment of early active RA.
(Curr Ther Res Clin Exp. 2012;73:123–133) © 2012 Elsevier HS Journals, Inc. All rights
reserved.
Key words: adverse reactions, glucocorticoid, leflunomide, methotrexate,
rheumatoid arthritis.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, generally progressive, systemic, autoim-
mune inflammatory disease that affects an estimated 0.5% to 1.0% of the adult
Accepted for publication June 27, 2012. http://dx.doi.org/10.1016/j.curtheres.2012.06.001
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Current Therapeutic Researchpopulation worldwide. The disease has a huge economic effect and, if untreated,
20% to 30% of affected individuals become permanently work-disabled within 3
years of diagnosis.1
Currently, there is no cure for RA, and treatment is directed at limiting joint
amage, preventing loss of function, and decreasing pain. Drugs administered for
hese purposes include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-
odifying anti-rheumatic drugs (DMARDs), and glucocorticoids (GCs).2
Given the high failure rate of monotherapy for RA, there has been increasing
nterest in combining anti-rheumatic drugs that act at different pathologic sites of
A in the hope of attaining greater and/or more prolonged efficacy with no increase
n adverse events.3 A preliminary open-label trial that tested the efficacy, safety, and
otential medication interactions of combination therapy with leflunomide (LEF) and
ethotrexate (MTX) has recently been published by Weinblatt et al.4
Glucocorticoid therapy has been used for several decades, although there has been
ebate about its efficacy. In recent years, considerable concern has been generated over
he use of small dosages of GCs to treat RA. The therapeutic guidelines, revised in
002 by the American College of Rheumatology Subcommittee on Rheumatoid
rthritis,5 state that low-dose GC therapy is useful in treating RA. Glucocorticoids
have a pivotal role in the management of RA and many other rheumatic diseases.5
Approximately 60 years after their introduction into clinical practice, GCs still
represent the most important and most frequently used class of anti-inflammatory
drugs; 25% to 75% of patients with RA receive GC therapy more or less continu-
ously.6 Recent studies have established the disease-modifying potential of low-dose
GC therapy for RA, and have renewed the debate about the risk versus benefit of this
treatment.7,8 Bijlsma and da Silva9 have argued that high dosages of GCs are
associated with adverse effects including fracture, hyperlipidemia, infectious disease,
and diabetes, among others. There is no doubt that, when used incorrectly, GCs have
high potential to cause frequent and serious adverse effects, which can be prevented
with prudent use.
Clinically active RA is usually treated using GCs in combination with other
medications such as DMARDs.10 Such therapy would enhance the adverse reaction
or therapeutic effects due to drug-drug interactions, which is determined by
factors such as target point, absorption, metabolism, and excretion.11 Curtis et
l12 have reported that despite the efficacy of MTX plus LEF therapy, liver
nzyme levels could become elevated and should be monitored during treatment.
hus, clinically relevant drug-drug interactions must be recognized in a timely
anner and be managed appropriately to prevent adverse drug reactions or
herapeutic failure, in particular when GCs are combined with MTX and LEF
ecause of the adverse effects induced.
The objectives of the present study were to clarify the adverse effects of therapy
ith GCs used in combination with LEF and MTX and to develop clinical practice
uidelines for use and dosage of GCs in active arthritis and established RA, over the
ong term and during disease flare-ups.
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C.-z. Ding et al.MATERIALS AND METHODS
Patients
The present study was conducted from January 1, 2008 to July 30, 2011. Patients
ith early active RA (2 years’ duration according to the revised 1987 American
ollege of Rheumatology criteria) were selected randomly from those receiving
reatment at the Department of Rheumatology and Immunology, The Affiliated
rum Tower Clinical Hospital of Nanjing University of Chinese Medicine.13 Inclu-
ion criteria were presence of 2 of the following 3 symptoms: swollen joint count3;
ender joint count 8; and average duration of morning stiffness 45 minutes,
rythrocyte sedimentation rate 28 mm/h, and C-reactive protein level 1.5-fold
he upper limit of normal. All patients with RA who had not used DMARDs (MTX,
ulfasalazine, and anti-malarial drugs) or GCs in the past 3 months were considered
or participation in the study. Excluded were patients with other immune system
isorders, hypertension, diabetes, heart disease, osteoporosis, pre-existing liver dis-
ase, hematologic system disease, and peptic ulcer; those who were pregnant or
actating, or had drug allergies; and those in whom immunodepression was contra-
ndicated. Consent from our institutional ethics committee was obtained. Informed
ritten consent was obtained from all patients who participated in the study.
Procedure
Patients were randomized to receive GCs or placebo along with 20 mg/d LEF and
0 mg/wk MTX. Patients were divided into 3 groups, as follows: group 1 received
lacebo, group 2 received 7.5 mg/d prednisone, and group 3 received 15 mg/d
rednisone. The study sponsor, investigators, and patients were blinded to treatment
llocation until week 12.
Disease activity scores in 28 joints, C-reactive protein level, average duration of
orning stiffness, and erythrocyte sedimentation rate were used to evaluate the
athogenesis of RA via review of the literature.14 Care should be taken that adverse
effects are treated in a timely manner with suitable therapy such as concomitant
NSAIDs, after considering the pathogenesis, and calcium, alfacalcidol, or calcitriol if
osteoporosis develops. Patients with serious hepatic adverse effects should be with-
drawn from the trial immediately.
Bone mineral density of the lumbar spine and femur neck was measured using
dual-energy X-ray absorptiometry both before initiation of therapy and at 6 months
after therapy by 2 independent expert radiologists blinded to treatment and sequence.
According to the diagnostic criteria recommended by the World Health Organiza-
tion, osteoporosis is defined as bone density 2.5 SD lower than that of age- and
sex-matched healthy adults (T2.5). To clarify, light density method is the study
of T-value, which is bone mineral density comparison value between patient and
young people with the corresponding gender and race. Patients whose T value was
below 2.5 SD would be diagnosed with osteoporosis.
The dosage, course of treatment, and details of combination therapy were recorded
every 4 weeks, as well as an evaluation of general health including blood pressure,
blood glucose concentration, and leukocyte count, and presence of enteron symptoms,
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Current Therapeutic Researchsuch as nausea and vomiting, hyperlipidemia, rash, mouth ulcers, hepatic lesions,
osteoporosis, and nontraumatic fracture. The correlation between GC use and these
adverse effects was analyzed at weeks 4 and 12. Adverse events were recorded
throughout the study, and were graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events, version 3.
Statistical Analysis
Statistical analysis was performed using commercially available software (SPSS version
0; SPSS, Inc, Chicago, Illinois). Variables included age, sex, pathogenesis, and disease
ctivity scores in the 3 groups. Comparisons of frequency of adverse events and
herapeutic effects between the 3 groups were analyzed using the rank sum, 2, and
Mann-Whitney U tests. P  0.05 was considered significant.
RESULTS
Two hundred sixty-six patients were randomized into 3 groups. Their baseline
demographic data and disease characteristics are given in Table I. There was no
significant difference between the 3 groups insofar as age, sex, pathogenesis, and
disease activity score (P  0.05).
The flow of patients through the study is shown in Figure 1. The trial was
completed by 88.9%, 96.6%, and 97.7% of patients in groups 1, 2, and 3,
respectively. During weeks 0 to 4, the number of patients withdrawn from the
study was 4, 1, and 0 in groups 1, 2, and 3, respectively, because of serious
adverse events or lack of efficacy. During weeks 4 to 12, the number of patients
withdrawn was 6, 2, and 2, respectively, because of adverse reactions, loss to
follow-up, or lack of efficacy (Figure 1). Other comparatively minor adverse
effects resolved with treatment. Assessment of bone density found that 1 patient
with nontraumatic fracture had osteoporosis. Adverse reactions are detailed in
Table I. Baseline characteristics of the structural study by group.*
Variable
Group 1
No GC
Group 2
7.5 mg GC
Group 3
15 mg GC Statistic P
No. of patients 90 88 88 NA NA
ex 2  0.28 0.87
Male 13 12 14
Female 77 76 74
ge at onset of disease, y 45.4 (13.8) 39.9 (18.7) 43.8 (13.7) F  2.76 0.07
uration of disease, y 3.6 (2.1) 3.6 (2.1) 2.7 (2.3) F  2.12 0.12
AS score before treatment 6.4 (2.1) 6.8 (2.5) 6.9 (3.5) F  2.25 0.25
DAS  disease activity score; GC  glucocorticoid therapy; NA  not applicable.
*Unless otherwise understood, data are given as mean (SD).Figure 2 and Tables II and III.
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C.-z. Ding et al.Some patients in each group were given NSAIDs simultaneously with study drug,
ith no disparity in percentage of patients between the 3 groups (P 0.05). Patients
n groups 2 and 3 received combination therapy with calcium, alfacalcidol, or
alcitriol. No patients in any of the 3 groups received folacin.
DISCUSSION
Methotrexate, a folate antagonist, was first developed for treatment of malignant
diseases, and currently is used to treat graft-versus-host disease, RA, and other chronic
inflammatory disorders.15 Low concentrations of MTX are effective in controlling the
nflammatory manifestations of RA when combined with LEF, an RA-specific drug
hat selectively inhibits de novo pyrimidine synthesis by blocking the rate-limiting
nzyme dihydroorotate dehydrogenase.16
With recognition of RA, there has been consensus about the use of combination
herapy using DMARDs early in the course of the disease. Numerous studies have
uggested that combined LEF and MTX therapy was effective in RA.17 It has been
ecommended that GCs are able to relieve arthralgia if given shortly after an acute
pisode or in patients with poor function of the heart, lungs, eyes, and nervous
ystem.18 The GC dosage should be adjusted according to the pathologic condition.19
There has been much debate about the approach, dosage, and duration of treatment
with GCs because of their unavoidable adverse effects.20 Accordingly, increased
ttention should be focused on the adverse effects of combination therapy with
266 Patients randomly assigned
88 Patients, 7.5 mg GC,
MTX+LEF
90 Patients, placebo +
MTX+LEF
88 Patients, 15 mg GC,
MTX+LEF
0 Patients withdrawn  Weeks 0 to 4
Weeks 4 to 12
2 Patients withdrawn
(adverse events)
2 Patients withdrawn
(1 lost to follow-up,
1 lack of efficacy)
6 Patients withdrawn
(3 adverse events,
3 lost to follow-up)
80 Patients (88.9%) 
completed 12 weeks
85 Patients (96.6%) 
completed 12 weeks
86 Patients (97.7%) 
completed 12 weeks
1 Patient withdrawn
(adverse events)
4 Patients withdrawn
(3 adverse events,
1 lack of efficacy)
Figure 1. Patient disposition. Patients were grouped according to the treatment received
(see “Materials and Methods”). LEF  leflunomide; MTX  methotrexate.MARDs and GCs.
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Current Therapeutic ResearchCombination therapy could be synergized or antagonised for different metabolism
rocedure or target cell. As a result, the curative effect could be raised or sup-
ressed.21 In addition, the incidence of adverse effects could be increased or decreased.
hus, more attention should be paid to adverse effects caused by combination
herapy.
In the present study, LFF and MTX combined with GCs was used to treat RA.16,22
Compared with group 1, at 12 weeks, patients in groups 2 and 3 had a lower
incidence of rash, and more patients in group 3 had hyperlipidemia (P  0.05).
rom 4 to 12 weeks, the incidence of rash, mouth ulcers, increased alanine
minotransferase concentration, and leukocytepenia in group 1 was significantly
igher than in groups 2 and 3 (P  0.05). However, the incidence of osteoporosis,
Group 1 Group 2 Group 3
Group 1 Group 2 Group 3 Group 1 Group 2 Group 3
Group 1 Group 2 Group 3
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Figure 2. Comparisons of the incidence of rash, increase in alanine aminotransferase
(ALT) concentration, diabetes, and hyperlipidemia in the 3 groups at weeks 4 to
12. Almost all adverse reactions at week 12 were higher than at week 4, in
particular, rash and increase in ALT in group 1, and diabetes and hyperlipidemia
in group 3. In addition, at week 4, the incidence of the 4 adverse effects in group
2 was relatively lower than in groups 1 and 3. Group 1, no glucocorticoid therapy
(GC); group 2, 7.5 mg GC; and group 3, 15 mg GC. *P < 0.05 (significant
difference).yperglycemia, and hyperlipidemia was higher in group 3 (P  0.05). Analysis
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C.-z. Ding et al.demonstrated that there was little advantage to long-term use of GCs at a dose
of 15 mg/d. However, further study is necessary to determine the influence of GCs
on osteoclasis.
Table II. Incidence of adverse effects at 4 weeks of treatment.*
Adverse Effect
Group 1
No GC
(n  86)
Group 2
7.5 mg GC
(n  87)
Group 3
15 mg GC
(n  88) Statistic P
Rash 8.1 (n  7) 2.3† (n  2) 0† (n  0) 2  9.17 0.01
Mouth ulcer 14 (n  12) 6.9 (n  6) 6.8 (n  6) 2  3.44 0.18
ALT increase 10.47 (n  9) 5.7 (n 5) 6.8 (n  6) 2  0.87 0.65
Leukocyte decrease 8.1 (n 7) 2.3 (n  2) 2.3 (n  2) 2  1.49 0.15
Nontrauma fraction 0 0 0 NA NA
Diabetes 3.8 (n  4) 3.5 (n  3) 4.7 (n  4) 2  1.87 1.00
Hyperlipidemia 1.2 (n  1) 2.3 (n  2) 8† (n  7) 2  6.28 0.04
Hypertension 1.2 (n  1) 2.3 (n  2) 1.1 (n  1) 2  0.51 0.88
Gastrointestinal
symptoms 7 (n  6) 9.2 (n  8) 9.1 (n  8) 2  0.35 0.67
Combined NSAIDs 82.5 (n 66) 84.7 (n  72) 86 (n  74) 2  1.74 0.86
ALT  alanine aminotransferase; NA  not applicable; NSAIDs  nonsteroidal anti-inflammatory drugs.
*Data are given as percentage (number of patients).
†Denotes significant difference between the 3 groups.
Table III. Incidence of adverse effects at weeks 4 to 12 during treatment.*
Adverse Effect
Group 1
No GC
(n  80)
Group 2
7.5 mg GC
(n  85)
Group 3
15 mg GC
(n  86) Statistic P
Rash 11.3 (n  9) 2.4† (n  2) 0† (n  0) 2  12.65 0.01
outh ulcer 15.5 (n 11) 4.2 (n  3) 2.9† (n  2) 2  7.57 0.02
LT increase 23.9 (n 17) 7.3 (n  6) 9.3† (n  8) 2  7.44 0.02
eukocyte decrease 12.5 (n 10) 2.4 (n  2) 2.3† (n  2) 2  5.28 0.04
ontrauma fraction 0 0 1.2† (n  1) NA 0.001
Diabetes 3.8 (n  4) 9.4 (n 8) 15.1† (n  13) 2  5.38 0.001
yperlipidemia 2.5 (n  2) 3.5 (n 3) 12.7† (n  11) 2  9.65 0.008
ypertension 2.5 (n  2) 3.5 (n 3) 4.7 (n  4) 2  0.69 0.88
astrointestinal
ymptoms 10 (n  8) 11.8 (n 10) 11.6 (n  10) 2  0.34 0.62
ombined NSAIDs 75 (n 60) 65.9 (n 56) 79.1 (n  68) 2  3.87 0.86
ALT  alanine aminotransferase; NA  not available; NSAIDs  nonsteroidal anti-inflammatory drugs.
*Data are given as percentage (number of patients).
†Denotes significant difference between the 3 groups.
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Current Therapeutic ResearchIt has been reported that LEF increased levels of hepatic enzymes, which are
etabolised in the liver and have a long half-life.12 However, LEF shares the same
metabolism site with traditional anti-rheumatic agents such as MTX.23 Therefore,
iver dysfunction is more likely to develop when LEF and MTX are used in combi-
ation.24 One study has suggested that the hepatic adverse effects caused by LEF
ight be related to dihydroorotate dehydrogenase gene polymorphism.25
Supersensitive skin reactions induced by LEF are relatively common, and
nclude rash and purpua, 90% of which resolve after withdrawal of the drug.26
Stevens-Johnson syndrome or toxic epidermal necrolysis occurs relatively rarely.
The skin reaction induced by LEF might be due to active cellular proliferation.20
The neutropenia may be due to the bone marrow depressive function of LEF and
MTX.10,27
It has been reported that adverse reactions to LEF and MTX could be reduced when
ombined with GCs.28,29 No serious adverse effects were found in our study. It is
hought that GC might affect metabolism, the enzymatic system, and pharmacoki-
etics and medication interactions. Future investigations into the mechanism of GC
hat reduces adverse reactions caused by the combination of LEF and MTX are
ecessary.
Boers et al30 have suggested that blood lipid concentrations in patients admin-
strated low-dose GCs combined with anti-rheumatic agents was lower than in
hose who received DMARD therapy alone, although GCs could increase the risk
f hyperlipidemia. As a result, most researchers believe that for long-term
herapy, low-dose GCs should not be used alone, but in combination with
nti-rheumatic agents.
Recent research has indicated that low-dose GCs do not increase the risk of
ypertension or diabetes.31 Patients with chronic inflammation commonly have
hyperglycemia due to insulin resistance in peripheral tissues and insulin secretion
depression by inflammatory substances, which could be reversed with GC therapy.32
In the present study, the incidence of hypertension, diabetes, and hyperlipidemia
in the low-dose group showed no significant increase, which supports this
conclusion. Blood pressure and glucose concentrations in patients in group 3
remained normal at 4 weeks, which may be due to the severity of the inflamma-
tion. When the inflammation was controlled after 4 weeks, the adverse effects
induced by GCs increased.
Osteoporosis and bone fracture are the most common GC-associated adverse
reactions.33,34 Some studies have indicated that the incidence of osteoporosis would
e increased with use of low-dose GC therapy.35 However, during the study, no
atients in the low-dose group sustained a nontraumatic fracture, and no patients in
roup 3 experienced nontraumatic fracture until week 4 (P  0.05), which might be
ue to the administration of calcium and alfacalcidol. From weeks 4 to 12, in group
, osteoporosis developed in 11 patients, and 1 patient sustained a nontraumatic
racture. This indicated that in patients given 15-mg GC therapy, osteoporosis was
ikely to develop after 4 weeks.
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C.-z. Ding et al.CONCLUSION
Compared with control patients given placebo, in patients with RA, clinical signs and
symptoms and laboratory test results improved with LEF and MTX therapy com-
bined with various dosages of GCs. The adverse effects induced by MTX and LEF
were decreased by adding GCs to the therapy. When combined with low-dose GC
therapy, blood pressure and glucose concentration remain stable, although blood lipid
concentrations may increase. It is necessary to add calcium and alfacalcidol to prevent
osteoporosis. If treatment with 15 mg GC is administered over the long term,
appropriate measures should be taken to prevent osteoporosis, and blood pressure and
blood glucose and lipid concentrations should be monitored.
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